Cellectis S.A. (CLLS) stock
CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 20, 2026Score 3/30
$1.06+0.02 (+1.92%)
Close on Nov 17, 2026Market cap $106.36MP/E –Yield –
Cellectis gross margin
Gross margin is gross profit as a percentage of revenue.
For fiscal 2025 it was 100.0%, against 100.0% the year before. The highest annual figure on record is 100.0% in fiscal 2024.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 100.0% | +0.0 |
| FY2024 | Dec 31, 2024 | 100.0% | +97.6 |
| FY2023 | Dec 31, 2023 | 2.4% | −88.4 |
| FY2022 | Dec 31, 2022 | 90.8% | −3.2 |
| FY2021 | Dec 31, 2021 | 93.9% | −2.3 |
| FY2020 | Dec 31, 2020 | 96.2% | +71.2 |
| FY2019 | Dec 31, 2019 | 25.0% | −53.5 |
| FY2018 | Dec 31, 2018 | 78.5% | −11.1 |
| FY2017 | Dec 31, 2017 | 89.6% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2023 | Jun 30, 2023 | 69.1% | +39.8 |
| Q2 FY2022 | Jun 30, 2022 | 74.8% | – |
| Q2 FY2021 | Jun 30, 2021 | -5.2% | – |
| Q2 FY2020 | Jun 30, 2020 | -100.9% | – |
| Q2 FY2019 | Jun 30, 2019 | 29.3% | – |
See a number that looks wrong?